Drug Database
DE

delivery technology (CEFORM EA / CEFORM RA / CEFORM)

✓ Approved

Bausch Health Companies Inc. · therapeutic agent

What is delivery technology?

delivery technology is a therapeutic agent developed by Bausch Health Companies Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCEFORM EA, CEFORM RA, CEFORM
CompanyBausch Health Companies Inc.
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Bausch Health Companies Inc.

Therapeutic Indications

delivery technology is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedHuman gene therapy2026-09-19

Practical Considerations for Gene and Cell Therapy Delivery in Temporal Lobe Epilepsy and Other Neurological Disorders.

Feller Christina C, Young Sarah C SC, Gupta Kunal K

Biological cell and gene approaches have great potential to provide durable, disease-modifying therapies for, as yet, incurable neurological disorders. The central nervous system (CNS), unlike other organ systems, however, poses unique challenges for access for biological therapies. Access challenges include physical barriers such as the blood-brain barrier, technical barriers such as procedural considerations, and variability in response to biological therapies that are dependent on route of delivery. In this review, these challenges are discussed along with the practicalities of therapeutic access for biological therapies to the CNS by systemic intravenous (IV) delivery, intrathecal delivery, and direct intraparenchymal delivery in the context of epilepsy and with relevance to other neurological disorders. In the context of IV delivery, the practicalities of CNS target and off-target systemic effects are discussed. In the context of intrathecal delivery, the practicalities of procedural access, cerebrospinal fluid dynamics, and tissue penetrance are reviewed. Finally, in the context of direct intraparenchymal delivery, the technical aspects of therapy administration, local and systemic spread, and immune response are highlighted. Each delivery method provides a different balance of procedural, targeting, and inflammatory considerations, which may affect future therapeutic agent selection and trial design. This framework highlights that delivery-route selection should be individualized according to therapeutic modality, target anatomy, desired distribution, procedural risk, and clinical infrastructure.

PMID 42760778
Read full article →
PubMedFrontiers in public health2026-09-19

If you build it, they will stay! Sustaining evidence-based practices for the treatment of substance use disorders through investment in workforce retention.

Chaple Michael J MJ, Becker Sara S, Freese Thomas E TE, Hartzler Bryan B et al.

Much attention has been paid to the persistent gap between the development of effective, evidence-based practices (EBPs) for substance use disorders (SUDs) and their routine delivery in real-world clinical and community settings. The struggle to routinely implement and sustain EBPs with fidelity has been attributed to a combination of systemic, organizational and provider-level barriers. These barriers are compounded by high rates of staff turnover, as behavioral health systems must continuously reinvest in professional development despite their limited resources. Intermediary Purveyor Organizations (IPOs) such as the Addiction Technology Transfer Centers (ATTCs) have been engaged to support capacity building within agencies or systems to implement and sustain EBPs but must also contend with these challenges. As we expand implementation science efforts to explore the contextual factors that influence EBP implementation, including the impact of IPOs, it is important to consider that failure to improve staff turnover rates will only undermine these scientific investments. From the perspective of purveyors of technical assistance, the authors first reflect on the landscape of staff turnover, then offer system- and organization-level strategies for improving staff retention rates.

PMID 42760982
Read full article →
PubMednpj soft matter2026-09-19

Soft bioelectronics for wireless drug delivery: programmable, minimally invasive and closed-loop therapeutics.

Zhang Feng F, Sun Fuchang F, Yan Zheng Z

Soft bioelectronics is reshaping drug delivery from passive dosing to programmable, tissue-interfaced therapeutics. This Review examines the co-design of soft materials, wireless power, drug reservoirs, release mechanisms and feedback control for wearable and minimally invasive implantable therapeutic systems. We organize the field around key constraints including controllability, reversibility, payload capacity, dosing precision, drug stability and feedback latency, guiding the development of adaptive closed-loop drug delivery platforms for clinical translation.

PMID 42761000
Read full article →
PubMedBiomaterials translational2026-09-19

Transforming therapeutics through biomaterials: A comprehensive insight into biomaterials' role in effective drug delivery and healthcare advancement.

Dewali Seeta S, Sharma Netra Pal NP, Bhatt Pankaj P, Kathayat Neha N et al.

Biomaterials are engineered substances designed to interact with biological systems for therapeutic or diagnostic purposes. Their inherent properties-including biocompatibility, biodegradability, and structural versatility-have driven major advancements in drug delivery technologies. The global biomaterials market size was estimated at USD 178.0 billion in 2023 and is projected to grow at a compound annual growth rate of 15.6% from 2024 to 2030. The growing incidence of musculoskeletal and chronic skeletal disorders is expected to drive demand for biomaterial-based implants, thereby contributing to market expansion. This review critically examines biomaterials, focusing on their classification into biobased, biodegradable, and biocompatible categories and analyzes their physicochemical properties and functional benefits. It highlights their applications in oncology, cardiovascular therapy, neurodegenerative diseases, and vaccination. Key challenges-including immunogenicity, cytotoxicity, and manufacturing complexities-are discussed, emphasizing the need for rigorous evaluation and adaptive regulatory frameworks. The review also explores recent advances in smart biomaterials for precision drug delivery, underscoring their potential to revolutionize personalized medicine through targeted, efficient, and patient-specific therapies.

PMID 42760964
Read full article →
PubMedJournal of applied toxicology : JAT2026-09-19

Adding Treatment-Continuity Metrics to Opioid Toxicity Investigation: A Triangulation Hypothesis for Applied Toxicology.

Huang Yu-Wen YW, Wei Lien-Chung LC

Fatal opioid toxicity is proximally mediated by respiratory depression, but whether an opioid exposure becomes lethal depends on opioid identity, dose, potency, route, tolerance, co-intoxicants, naloxone availability, and the response environment. Interruption of opioid agonist treatment (OAT) may alter several of these conditions through medication-uncovered time, withdrawal-driven re-exposure, tolerance change, and loss of clinical contact. We position treatment continuity as an additional time-varying exposure for overdose investigation, not as a substitute for or presumed priority over recent release from custody, treatment cessation, polydrug use, use in isolation, or lack of naloxone. We hypothesize that adding a time-resolved OAT continuity timeline to established person-, agent-, and environment-level variables will improve identification of modifiable pathways to fatal and nonfatal opioid toxicity. Its contribution is expected to vary by OAT medication and dose, treatment phase, supervised or take-home delivery, accessibility, and accompanying interventions. We propose triangulation across postmortem or clinical toxicology, longitudinal treatment and dispensing records, health and correctional data, and structured event review. A Haddon matrix organizes determinants across pre-event, event, and postevent phases. Core measures include documented OAT coverage-gap days, time to reassessment and relinkage, dose and delivery conditions, transition context, co-intoxicants, naloxone coverage, and rescue timing. Taiwan is presented as an instructive access setting rather than a universal delivery model. The hypothesis is testable through linked time-updated cohorts, within-person analyses, policy evaluations, and structured mortality and near-fatal-event review.

PMID 42760834
Read full article →
PubMedArchives of sexual behavior2026-09-19

Why Do Male Users Engage with Connected Sex Toys? A Latent Class Analysis of Motivational Profiles.

Lafortune David D, Dussault Éliane É, Canivet Cloé C, Williams Madison E ME et al.

Teledildonics are internet-connected sex toys enabling remote and interactive sexual experiences. Despite growing adoption, factors driving engagement with teledildonics remain underexplored. Clarifying how user motivations intersect to form distinct profiles is crucial for advancing theoretical models of sexual behavior and technology adoption. This study draws on a secondary analysis of cross-sectional survey data from customers of one teledildonics company. Using latent class analysis, we identified motivational patterns among male users (N = 569) across five indicators (arousal enhancement, relaxation, sexual satisfaction in a partner's absence, boredom relief, and technology integration) and examined associations between latent class membership and sociodemographics (e.g., age, sexual orientation, relationship status), usage modalities (i.e., frequency, concurrent pornography use, sex toy type), and sexual satisfaction. A four-class solution best fit the data. Solo Comfort Seekers (Class 1, 38.2%) strongly endorsed partner-substitution motives and were characterized by regular pairing with pornography. Low-Regulation Users (Class 2, 30.3%) showed the weakest endorsement of relaxation and boredom relief. Standalone Toy Users (Class 3, 22.6%) showed the lowest endorsement of technological integration and favored manual devices. Tech-Integrated Regulators (Class 4, 8.9%) moderately to strongly endorsed all motives and almost always used teledildonics with pornography. This study shows that teledildonics practices are embedded in complex individual and relational contexts, shaped by more than the pursuit of sexual pleasure. Recognizing these diverse profiles can inform theory, guide inclusive device design, and support tailored health promotion that advances sexual well-being and responds to evolving forms of intimacy.

PMID 42760476
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about delivery technology